LeonaBio (LONA) Equity Average (2019 - 2026)

LeonaBio (LONA) has 8 years of Equity Average data on file, last reported at $38.5 million in Q1 2026.

• Quarterly Equity Average fell 6.18% year-over-year to $38.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.5 million (down 6.18% YoY) and the FY2025 annual result came in at $36.3 million, down 58.5% from the prior year.
• Equity Average grew to $38.5 million in Q1 2026 per LONA's latest filing, from $27.3 million in the prior quarter.
• Across five years, Equity Average topped out at $311.5 million in Q1 2022 and bottomed at $27.3 million in Q4 2025.
• The 5-year median for Equity Average is $118.5 million (2024), against an average of $139.0 million.
• The widest annual swing landed in 2022, when Equity Average declined 2.26%; it then slumped 65.32% in 2025.
• Tracing LONA's Equity Average over 5 years: stood at $248.7 million in 2022, then slumped by 42.71% to $142.5 million in 2023, then slumped by 64.06% to $51.2 million in 2024, then sank by 46.72% to $27.3 million in 2025, then soared by 41.26% to $38.5 million in 2026.
• Per Business Quant, the three latest LONA Equity Average figures stand at $38.5 million (Q1 2026), $27.3 million (Q4 2025), and $29.4 million (Q3 2025).

Peer Comparison